| # | Drug | Count |
|---|---|---|
| 0 | PANITUMUMAB | 35 |
| 1 | FLUOROURACIL | 23 |
| 2 | FLUOROURACIL CREAM, 0.5% | 23 |
| 3 | OXALIPLATIN | 23 |
| 4 | CETUXIMAB | 16 |
| 5 | ERLOTINIB HYDROCHLORIDE | 11 |
| 6 | BEVACIZUMAB | 10 |
| 7 | ERLOTINIB | 9 |
| 8 | DOXYCYCLINE | 8 |
| 9 | DOXYCYCLINE HYCLATE | 8 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | PYCNOGENOL 6X | 1 | 0.0116 |
| 1 | FUTIBATINIB | 1 | 0.0045 |
| 2 | PEMIGATINIB | 2 | 0.0023 |
| 3 | PANITUMUMAB | 35 | 0.0022 |
| 4 | LATANOPROST OPHTHALMIC SOLUTION 0.005% | 1 | 0.0016 |
| 5 | LAZERTINIB | 1 | 0.0012 |
| 6 | ERLOTINIB HYDROCHLORIDE | 11 | 0.0009 |
| 7 | ERDAFITINIB | 1 | 0.0008 |
| 8 | CETUXIMAB | 16 | 0.0005 |
| 9 | CALCIUM FOLINATE | 2 | 0.0004 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Epidermal Growth Factor Receptor Antagonist [EPC] | 51 | 0.0011 |
| 1 | Tetracycline-class Drug [EPC] | 8 | 0.0001 |
| 2 | Provitamin D2 Compound [EPC] | 3 | 0.0001 |
| 3 | Platinum-based Drug [EPC] | 27 | 0.0001 |
| 4 | Nucleoside Metabolic Inhibitor [EPC] | 25 | 0.0001 |
| 5 | Vascular Endothelial Growth Factor Inhibitor [EPC] | 10 | 0.0001 |
| 6 | Prostaglandin Analog [EPC] | 4 | 0.0000 |
| 7 | Serotonin-1b and Serotonin-1d Receptor Agonist [EPC] | 1 | 0.0000 |
| 8 | Nucleoside Analog Antiviral [EPC] | 3 | 0.0000 |
| 9 | Leukocyte Growth Factor [EPC] | 2 | 0.0000 |